Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
about
Current status of active surveillance in prostate cancerThe role of magnetic resonance imaging in the diagnosis and management of prostate cancerCan contemporary patients with biopsy Gleason score 3+4 be eligible for active surveillance?Integration of multiparametric MRI into active surveillance of prostate cancer.Using Electronic Health Record Data to Identify Prostate Cancer Patients That May Qualify for Active Surveillance.Identification of pathologically insignificant prostate cancer is not accurate in unscreened men.Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsySeventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.Active surveillance in men with low-risk prostate cancer: current and future challenges.Five-year follow-up of active surveillance for prostate cancer: A Canadian community-based urological experience.Is active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillance.Our results of active surveillance for localized prostate cancer patients.Insignificant disease among men with intermediate-risk prostate cancerAnalysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.Gleason score 6 adenocarcinoma: should it be labeled as cancer?Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer.Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical OverviewTiming of curative treatment for prostate cancer: a systematic review.Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment.Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance.Multiparametric magnetic resonance imaging and active surveillance: How to better select insignificant prostate cancer?Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men.In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillanceNeutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.The biopsy Gleason score 3+4 in a single core does not necessarily reflect an unfavourable pathological disease after radical prostatectomy in comparison with biopsy Gleason score 3+3: looking for larger selection criteria for active surveillance caCan you un-ring the bell? A qualitative study of how affect influences cancer screening decisions.An assessment of Prostate Cancer Research International: Active Surveillance (PRIAS) criteria for active surveillance of clinically low-risk prostate cancer patients.The effect of urologist experience on choosing active surveillance for prostate cancer.Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.Performance of biopsy factors in predicting unfavorable disease in patients eligible for active surveillance according to the PRIAS criteria.The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort.Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols.A urine-based methylation signature for risk stratification within low-risk prostate cancer.Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance.Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring.Patient selection and pathological outcomes using currently available active surveillance criteria.Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate.Prostate cancer and the increasing role of active surveillance.
P2860
Q26766307-918F77A7-A41B-42F8-90F9-F07FC40557A7Q26849794-439DDED7-D3B0-41F2-B7BC-E6E1A38C6B4CQ28543448-99D59BE9-10F6-4C53-B266-67C2BE2D2E0FQ30249514-04B5853D-36D5-491F-8117-58F022924DC8Q31133702-A2D1B340-28B3-4E0D-9600-EBF0D64DFB7EQ33613656-CD8AE93F-0C28-459D-962E-C9172F696D11Q33717988-E4803771-90B5-44AF-875A-B6D05548C2E7Q33905899-C19B3888-CE91-4A49-9770-576174599E0CQ34448113-CBBDC70D-D2D9-4013-A468-08AABFFECE2DQ34602101-1882FCF6-1628-4A26-9DF8-C5AA53568CF7Q35173116-055DC1DF-A8F1-48CA-820E-8539AE21D1B7Q35993855-32BA3FFB-B15F-4733-AF1D-7C3EEB9B1F35Q36022444-F9CEC553-9331-4D43-931D-EB591D506F3EQ36293085-DC412EFA-783E-4169-BBA8-2CC8487257A1Q36449197-096B2B23-71A0-4E7F-861E-CB1B1DC0FED4Q36935758-134E3A9E-3F3A-4734-AD6D-E53E0B4A721FQ36979944-744405B3-6F53-4AFA-8074-928801E0DA35Q37201922-D5A2EEEA-C659-45DF-AC5D-86167195239AQ38568583-1358D599-E748-4C06-A5CB-469E4AFF89FAQ38846321-4E848A68-966F-40FB-BBF8-4D0DF6C00D66Q38906488-FAFC12F6-17AC-4479-81C3-63C4A3341195Q39405854-7FC87FD6-8A85-4009-A0DF-DEA7ECA259DCQ39699690-0DFBFDAA-781A-4AE5-8EED-CB639FE9DE74Q40450047-38C1EDBA-FDB8-4B66-8566-B058F62F42CDQ40561072-97298763-8749-4C2A-AE54-4B57DA0A1062Q40572565-00E4B0DA-A8E9-47DB-B389-E0479D4D113AQ40856884-AF7E2F71-4BD2-4643-AF90-48A68E73DE25Q41109068-AA9EA585-7653-46E4-9A8E-9868786A4F6CQ41240355-C6DF89CF-01C1-4C90-A302-7EC18CBB7641Q41243409-3D405D4F-11D5-41D2-894A-02428C2FF9FCQ41599088-C83C204F-A514-4FAA-9C0C-E784CEFF986EQ41702572-5101D37D-1580-46D0-938C-E0A46598AA61Q41878045-6A82158D-216E-45C3-A5E0-0AFAAD84552DQ41992772-D4B44343-E9C6-496E-93BB-62DEDDBC3A50Q42121326-40EA05CD-8859-4002-9E2F-E8F21E4188D0Q42736742-AB032124-3B12-4CDF-B3D4-C7FEF88C7D1CQ42736743-CC95A0CA-8BD5-4936-B512-B3FBC2B8F4CFQ43756470-7418F42F-D70E-4E83-A013-B80E0B06A209Q44487866-CC999CA7-84EF-4220-9E5B-38ADE682D592Q46054276-72412DA5-A955-4445-91BC-5B43AD7B6F67
P2860
Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Pathologic prostate cancer cha ...... son of contemporary protocols.
@en
Pathologic prostate cancer cha ...... son of contemporary protocols.
@nl
type
label
Pathologic prostate cancer cha ...... son of contemporary protocols.
@en
Pathologic prostate cancer cha ...... son of contemporary protocols.
@nl
prefLabel
Pathologic prostate cancer cha ...... son of contemporary protocols.
@en
Pathologic prostate cancer cha ...... son of contemporary protocols.
@nl
P2093
P1433
P1476
Pathologic prostate cancer cha ...... son of contemporary protocols.
@en
P2093
Daniel L Rosenberg
Lisét Pelaez
Mark S Soloway
Mercé Jorda
Murugesan Manoharan
Viacheslav Iremashvili
P304
P356
10.1016/J.EURURO.2012.03.011
P407
P577
2012-03-17T00:00:00Z